ZIM
ALXN

Zacks Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Zacks Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,130
Closed -$208K – 671
2021
Q2 		$208K Buy
+1,130
New +$194K ﹤0.01% 560
2015
Q2 		– Sell
-7,138
Closed -$1.24M – 753
2015
Q1 		$1.24M Buy
7,138
+3,473
+95% +$629K 0.04% 250
2014
Q4 		$678K Sell
3,665
-129
-3% -$23.9K 0.02% 341
2014
Q3 		$629K Sell
3,794
-4,683
-55% -$769K 0.02% 351
2014
Q2 		$1.32M Buy
8,477
+1,808
+27% +$285K 0.05% 213
2014
Q1 		$1.01M Buy
6,669
+3,320
+99% +$528K 0.04% 248
2013
Q4 		$445K Buy
3,349
+515
+18% +$61.8K 0.02% 442
2013
Q3 		$329K Buy
2,834
+611
+27% +$67K 0.01% 488
2013
Q2 		$205K Buy
+2,223
New +$214K 0.01% 568

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Zacks Investment Management's ALXN Position: Q3 2021 in Review

Zacks Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,130 shares — an estimated $208K sold.

Zacks Investment Management first reported a position in ALXN in Q2 2013 and held it in 9 quarters. The position peaked at $1.32M in Q2 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Zacks Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Zacks Investment Management sold 1,130 Alexion Pharmaceuticals shares in Q3 2021, an estimated $208K.
  • Zacks Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 9 quarters.
  • Zacks Investment Management's Alexion Pharmaceuticals position peaked at $1.32M in Q2 2014.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Zacks Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.